Sprout Health vs AquaVita NextGen
Two GLP-1 desks, one scoreboard. We put Sprout Health and AquaVita NextGen head-to-head on the published Brief Score — the same six factors, scored the same way.
Sprout Health
AquaVita NextGen
The verdict
Sprout Health takes this head-to-head.
Sprout Health scores 86 to 67 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.
That doesn't make AquaVita NextGen a bad call — it's best for patients in az/ca/fl/tx/nv seeking medspa-backed glp-1 with a named medical director. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Sprout Health | AquaVita NextGen | |
|---|---|---|
| Brief Score | 86/100 (B) | 67/100 (C) |
| Semaglutide | $149/mo | From $375/mo (compounded) |
| Tirzepatide | $199/mo | From $320/mo (starting dose, compounded) |
| Coverage | Not disclosed | 5 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.
AquaVita NextGen: New to the tracker on 1 August 2026. The published line reads From $320/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Keep comparing
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.